Philadelphia-based Rothman Orthopaedic Institute has been at the forefront of spine care, and recently a team partnered with Thomas Jefferson University Hospita ...

Utilizing the Dural Substitute Confetti technique during spinal cord stimulation trial implantation may reduce complications and shorten surgery time.

Chris Patterson retired before Christmas 2022, after falling and breaking his back. He has faced several issues trying to get ...

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

The company is facing significant headwinds in its U.S. core Spinal Cord Stimulation (SCS) market, where sales have continued to decline and trials have decelerated, raising concerns about the company ...

A key highlight of the quarter came right at the end when Nevro won FDA approval for HFX AdaptiveAI, an AI-powered, ...

Q3 2024 Earnings Call Transcript November 11, 2024 Nevro Corp. beats earnings expectations. Reported EPS is $-0.51, expectations were $-0.81. Operator: Good afternoon. My name is Krista, and I will be ...

HFX iQ is the first and only spinal cord stimulation (SCS) system integrating high-frequency SCS landmark evidence ... The ...

The company announced receiving CE Mark Certification in Europe for its HFX iQ spinal cord stimulation system. Nevro raised ...

The webcast will be held on November 26, 2024, at 2:00PM CET / 08:00AM ET. It will be hosted by CEO Dave Marver who will discuss highlights from Q3 2024 and provide a business update. To join the ...

Company to provide update on significant milestones and near-term plans, including its recent successful financing and agreements with Ottobock and CEAEINDHOVEN, the Netherlands, Nov. 12, 2024 (GLOBE ...

Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ETCompany ParticipantsAngie McCabe - Vice President, Investor ...